ArticleScience translational medicine2021

cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes.

Kevin Roehle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.